Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read now.

Hepatitis E vaccine HEV 239 significantly reduces the risk of symptomatic hepatitis E among individuals with chronic hepatitis B. Read now.

EBV antibodies trigger MS by attacking brain proteins. Genetic factors worsen risk. Breakthrough insights for treatment.

While rheumatoid arthritis patients have a lower overall cancer incidence rate, they face higher post-cancer mortality.

A new study finds that cognitive decline in relapsing-remitting multiple sclerosis (RRMS) often occurs independently of relapses or MRI activity, highlighting the need for improved monitoring and ...

A large U.S. study finds that annual COVID-19 boosters provide significant protection against severe illness but lose effectiveness after six months.

A 12-month interim analysis of the AGILE Phase III extension study confirms the long-term safety and efficacy of twice-yearly depemokimab for patients with type 2 asthma.